135 related articles for article (PubMed ID: 15712318)
21. Expression and localization of atypical PKC isoforms in liver parenchymal cells.
Stross C; Keitel V; Winands E; Häussinger D; Kubitz R
Biol Chem; 2009 Mar; 390(3):235-44. PubMed ID: 19090727
[TBL] [Abstract][Full Text] [Related]
22. Bacterial expression and purification of C1 and C2 domains of protein kinase C isoforms.
Cho W; Digman M; Ananthanarayanan B; Stahelin RV
Methods Mol Biol; 2003; 233():291-8. PubMed ID: 12840516
[No Abstract] [Full Text] [Related]
23. Protein kinase Cs in lung cancer: a promising target for therapies.
Fan C; Li Y; Jia J
J Cancer Res Ther; 2013 Sep; 9 Suppl 2():S74-9. PubMed ID: 24135246
[TBL] [Abstract][Full Text] [Related]
24. Applications of inhibitors for protein kinase C and their isoforms.
Shen GX; Way KJ; Jacobs JR; King GL
Methods Mol Biol; 2003; 233():397-422. PubMed ID: 12840525
[No Abstract] [Full Text] [Related]
25. Protein kinase C--a novel target for rational anti-cancer drug design?
Gescher A; Dale IL
Anticancer Drug Des; 1989 Aug; 4(2):93-105. PubMed ID: 2679620
[No Abstract] [Full Text] [Related]
26. A candidate gene for human neurodegenerative disorders: a rat PKC gamma mutation causes a Parkinsonian syndrome.
Craig NJ; Durán Alonso MB; Hawker KL; Shiels P; Glencorse TA; Campbell JM; Bennett NK; Canham M; Donald D; Gardiner M; Gilmore DP; MacDonald RJ; Maitland K; McCallion AS; Russell D; Payne AP; Sutcliffe RG; Davies RW
Nat Neurosci; 2001 Nov; 4(11):1061-2. PubMed ID: 11600890
[No Abstract] [Full Text] [Related]
27. Synthesis and PKCtheta inhibitory activity of a series of 4-(indol-5-ylamino)thieno[2,3-b]pyridine-5-carbonitriles.
Boschelli DH; Wu B; Barrios Sosa AC; Chen J; Asselin M; Cole DC; Lee J; Yang X; Chaudhary D
Bioorg Med Chem Lett; 2008 May; 18(9):2850-3. PubMed ID: 18434148
[TBL] [Abstract][Full Text] [Related]
28. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
29. Optimization of 5-phenyl-3-pyridinecarbonitriles as PKCtheta inhibitors.
Boschelli DH; Wang D; Prashad AS; Subrath J; Wu B; Niu C; Lee J; Yang X; Brennan A; Chaudhary D
Bioorg Med Chem Lett; 2009 Jul; 19(13):3623-6. PubMed ID: 19447612
[TBL] [Abstract][Full Text] [Related]
30. The Dual Roles of the Atypical Protein Kinase Cs in Cancer.
Reina-Campos M; Diaz-Meco MT; Moscat J
Cancer Cell; 2019 Sep; 36(3):218-235. PubMed ID: 31474570
[TBL] [Abstract][Full Text] [Related]
31. Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit.
George DM; Breinlinger EC; Friedman M; Zhang Y; Wang J; Argiriadi M; Bansal-Pakala P; Barth M; Duignan DB; Honore P; Lang Q; Mittelstadt S; Potin D; Rundell L; Edmunds JJ
J Med Chem; 2015 Jan; 58(1):222-36. PubMed ID: 25000588
[TBL] [Abstract][Full Text] [Related]
32. Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.
Cole DC; Asselin M; Brennan A; Czerwinski R; Ellingboe JW; Fitz L; Greco R; Huang X; Joseph-McCarthy D; Kelly MF; Kirisits M; Lee J; Li Y; Morgan P; Stock JR; Tsao DH; Wissner A; Yang X; Chaudhary D
J Med Chem; 2008 Oct; 51(19):5958-63. PubMed ID: 18783200
[TBL] [Abstract][Full Text] [Related]
33. Irreversible inactivation of protein kinase C isozymes by thiol-reactive peptide substrate analogs.
O'Brian CA; Ward NE; Chu F; Stewart JR
Methods Mol Biol; 2003; 233():441-9. PubMed ID: 12840527
[No Abstract] [Full Text] [Related]
34. Protein kinase C isotypes and their specific functions: prologue.
Ohno S; Nishizuka Y
J Biochem; 2002 Oct; 132(4):509-11. PubMed ID: 12359062
[No Abstract] [Full Text] [Related]
35. Protein kinase C isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis.
Webb BL; Hirst SJ; Giembycz MA
Br J Pharmacol; 2000 Aug; 130(7):1433-52. PubMed ID: 10928943
[No Abstract] [Full Text] [Related]
36. [Heterogeneity of protein kinase C].
Zajac J
Postepy Biochem; 1989; 35(3):245-52. PubMed ID: 2700786
[No Abstract] [Full Text] [Related]
37. Crystallization of the protein kinase Cdelta C1B domain.
Zhang G; Hurley JH
Methods Mol Biol; 2003; 233():299-304. PubMed ID: 12840517
[No Abstract] [Full Text] [Related]
38. High-content assays in oncology drug discovery: opportunities and challenges.
Mouchet EH; Simpson PB
IDrugs; 2008 Jun; 11(6):422-7. PubMed ID: 18509783
[TBL] [Abstract][Full Text] [Related]
39. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications.
Budhiraja S; Singh J
Fundam Clin Pharmacol; 2008 Jun; 22(3):231-40. PubMed ID: 18485142
[TBL] [Abstract][Full Text] [Related]
40. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
McInnes C
Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
